Scientific Concept of the National Cohort (status ... - Nationale Kohorte

More documents

Recommendations

Info

C.3 References 691. Zenge, M.O., et al., High-resolution continuously acquired peripheral MR angiography featuring partial parallel imaging GRAPPA. Magn Reson Med, 2006. 56(4): p. 859-65. 692. Aldefeld, B., P. Bornert, and J. Keupp, Continuously moving table 3D MRI with lateral frequency-encoding direction. Magn Reson Med, 2006. 55(5): p. 1210-6. 693. Bornert, P. and B. Aldefeld, Principles of whole-body continuously-moving-table MRI. J Magn Reson Imaging, 2008. 28(1): p. 1-12. 694. Fautz, H.P. and S.A. Kannengiesser, Sliding multislice (SMS): a new technique for minimum FOV usage in axial continuously moving-table acquisitions. Magn Reson Med, 2006. 55(2): p. 363-70. 695. Kruger, D.G., et al., Dual-velocity continuously moving table acquisition for contrast-enhanced peripheral magnetic resonance angiography. Magn Reson Med, 2005. 53(1): p. 110-7. 696. Kruger, D.G., et al., Recovery of phase inconsistencies in continuously moving table extended field of view magnetic resonance imaging acquisitions. Magn Reson Med, 2005. 54(3): p. 712-7. 697. Kramer, H., et al., Peripheral magnetic resonance angiography (MRA) with continuous table movement at 3.0 T: initial experience compared with step-by-step MRA. Invest Radiol, 2008. 43(9): p. 627-34. 698. Kruger, D.G., et al., Continuously moving table data acquisition method for long FOV contrast-enhanced MRA and whole-body MRI. Magn Reson Med, 2002. 47(2): p. 224-31. 699. Vogt, F.M., et al., Peripheral vascular disease: comparison of continuous MR angiography and conventional MR angiography--pilot study. Radiology, 2007. 243(1): p. 229-38. 700. Baumann, T., et al., Continuously moving table MRI with sliding multislice for rectal cancer staging: Image quality and lesion detection. Eur J Radiol, 2009. 701. Baumann, T., et al., Detection of pulmonary nodules with move-during-scan magnetic resonance imaging using a free-breathing turbo inversion recovery magnitude sequence. Invest Radiol, 2008. 43(6): p. 359-67. 702. Bley, T.A., et al., Sliding multislice MRI for abdominal staging of rectal gastrointestinal stromal tumours. In Vivo, 2007. 21(5): p. 891-4. 703. Brauck, K., et al., Feasibility of whole-body MR with T2- and T1-weighted realtime steady-state free precession sequences during continuous table movement to depict metastases. Radiology, 2008. 246(3): p. 910-6. 704. Schaefer, J.F. and H.P. Schlemmer, Total-body MR-imaging in oncology. Eur Radiol, 2006. 16(9): p. 2000-15. 705. Sommer, G., et al., Sliding multislice MRI for abdominal staging of patients with pelvic malignancies: a pilot study. J Magn Reson Imaging, 2008. 27(3): p. 666-72. 706. Gebker, R., et al., Comparison of different MRI techniques for the assessment of thoracic aortic pathology: 3D contrast enhanced MR angiography, turbo spin echo and balanced steady state free precession. Int J Cardiovasc Imaging, 2007. 23(6): p. 747-56. 707. Utsunomiya, D., et al., Clinical role of non-contrast magnetic resonance angiography for evaluation of renal artery stenosis. Circ J, 2008. 72(10): p. 1627- 30. 328
329 References 708. Wilson, G.J. and J.H. Maki, Non-contrast-enhanced MR imaging of renal artery stenosis at 1.5 tesla. Magn Reson Imaging Clin N Am, 2009. 17(1): p. 13-27. 709. Smith, E.E., et al., MRI markers of small vessel disease in lobar and deep hemispheric intracerebral hemorrhage. Stroke, 2010. 41(9): p. 1933-8. 710. Polak, J.F., et al., Right ventricular ejection fraction: an indicator of increased mortality in patients with congestive heart failure associated with coronary artery disease. J Am Coll Cardiol, 1983. 2(2): p. 217-24. 711. Gloger, O., et al., A fully automatic three-step liver segmentation method on LDAbased probability maps for multiple contrast MR images. Magn Reson Imaging, 2010. 28(6): p. 882-97. 712. Huang, B.Y. and M. Castillo, Neurovascular imaging at 1.5 tesla versus 3.0 tesla. Magn Reson Imaging Clin N Am, 2009. 17(1): p. 29-46. 713. Huppertz, H.J., et al., Intra- and interscanner variability of automated voxel-based volumetry based on a 3D probabilistic atlas of human cerebral structures. Neuroimage. 49(3): p. 2216-24. 714. Kruggel, F., J. Turner, and L.T. Muftuler, Impact of scanner hardware and imaging protocol on image quality and compartment volume precision in the ADNI cohort. Neuroimage. 49(3): p. 2123-33. 715. Saam, T., et al., Reader and platform reproducibility for quantitative assessment of carotid atherosclerotic plaque using 1.5T Siemens, Philips, and General Electric scanners. J Magn Reson Imaging, 2007. 26(2): p. 344-52. 716. Theisen, D., et al., Myocardial perfusion imaging with Gadobutrol: a comparison between 3 and 1.5 Tesla with an identical sequence design. Invest Radiol, 2007. 42(7): p. 499-506. 717. Decramer, S., et al., Urine in clinical proteomics. Molecular & Cellular Proteomics, 2008. 7(10): p. 1850. 718. Thongboonkerd, V., Urinary proteomics: towards biomarker discovery, diagnostics and prognostics. Molecular BioSystems, 2008. 4(8): p. 810-815. 719. Ward, D.G., et al., Proteomic profiling of urine for the detection of colon cancer. Proteome Science, 2008. 6(1): p. 19. 720. Zürbig, P., et al., A low molecular weight urinary proteome profile of human kidney aging. Proteomics, 2009. 9(8): p. 2108. 721. Goodson, J.M., et al., Is obesity an oral bacterial disease? Journal of dental research, 2009. 88(6): p. 519. 722. Carvalho, A.L., et al., Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma. Clinical Cancer Research, 2008. 14(1): p. 97. 723. Hu, S., et al., Salivary proteomics for oral cancer biomarker discovery. Clinical Cancer Research, 2008. 14(19): p. 6246. 724. Hu, S., et al., Salivary proteomic and genomic biomarkers for primary Sjögren's syndrome. Arthritis & Rheumatism, 2007. 56(11): p. 3588-3600. 725. John, M.S., et al., IL-6 and IL-8: potential biomarkers for oral cavity and oropharyngeal SCCA. Otolaryngology-Head and Neck Surgery, 2004. 131(2): p. P112-P113. 726. Li, Y., et al., Salivary transcriptome diagnostics for oral cancer detection. Clinical Cancer Research, 2004. 10(24): p. 8442. C.3
Page 1:
The National Cohort A prospective e
Page 4 and 5:
Applicants Applicants Applicants Cl
Page 6 and 7:
Applicants IV
Page 8 and 9:
Executive Summary 2. The National C
Page 10 and 11:
Executive Summary 3. Scientific aim
Page 12 and 13:
Executive Summary essary to address
Page 14 and 15:
Executive Summary 7. Examples for s
Page 16 and 17:
Contents A.2.4 major areas of expos
Page 18 and 19:
Contents A.3.8.2 Social security da
Page 20 and 21:
Contents A.6.4.2 Minimally detectab
Page 22 and 23:
Abbreviations C.2 mEThOdS fOr STATI
Page 24 and 25:
Abbreviations DXA Dual-energy x-ray
Page 26 and 27:
Abbreviations CHS Cardiovascular He
Page 28 and 29:
A.1 A.1 Introduction and overview a
Page 30 and 31:
A.1 A.1 Introduction and overview s
Page 32 and 33:
A.1 A.1 Introduction and overview T
Page 34 and 35:
A.1 A.1 Introduction and overview m
Page 36 and 37:
A.1 A.1 Introduction and overview
Page 38 and 39:
A.1 A.1 Introduction and overview s
Page 40 and 41:
A.1 A.1 Introduction and overview
Page 42 and 43:
A.1 A.1 Introduction and overview P
Page 44 and 45:
A.1 A.1 Introduction and overview t
Page 46 and 47:
A.1 A.1 Introduction and overview A
Page 48 and 49:
A.2 A.2. Scientific background and
Page 50 and 51:
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Page 58 and 59:
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
A.3 A.3 Study design ment instrumen
Page 84 and 85:
A.3 A.3 Study design Table 3.2: Des
Page 86 and 87:
A.3 A.3 Study design Table 3.3: Dis
Page 88 and 89:
A.3 A.3 Study design the participan
Page 90 and 91:
A.3 A.3 Study design with a prepare
Page 92 and 93:
A.3 A.3 Study design rural areas, t
Page 94 and 95:
A.3 A.3 Study design A.3.2 Baseline
Page 96 and 97:
A.3 A.3 Study design Modules 70 Int
Page 98 and 99:
A.3 A.3 Study design ovarian carcin
Page 100 and 101:
A.3 A.3 Study design Table 3.5: Spe
Page 102 and 103:
A.3 A.3 Study design depression and
Page 104 and 105:
A.3 A.3 Study design to the extent
Page 106 and 107:
A.3 A.3 Study design ers to vaccina
Page 108 and 109:
A.3 A.3 Study design certain foods)
Page 110 and 111:
A.3 A.3 Study design A short instru
Page 112 and 113:
A.3 A.3 Study design ticipants and
Page 114 and 115:
A.3 A.3 Study design a resting time
Page 116 and 117:
A.3 A.3 Study design index, convent
Page 118 and 119:
A.3 A.3 Study design Although the i
Page 120 and 121:
A.3 A.3 Study design air and then t
Page 122 and 123:
A.3 A.3 Study design hemorrhages (0
Page 124 and 125:
A.3 A.3 Study design genetics of BM
Page 126 and 127:
A.3 A.3 Study design hand grip stre
Page 128 and 129:
A.3 A.3 Study design Project title
Page 130 and 131:
A.3 A.3 Study design diseases in va
Page 132 and 133:
A.3 A.3 Study design associations,
Page 134 and 135:
A.3 A.3 Study design Informed Conse
Page 136 and 137:
A.3 A.3 Study design 6. Since being
Page 138 and 139:
A.3 A.3 Study design the possible d
Page 140 and 141:
A.3 A.3 Study design A.3.5 Collecti
Page 142 and 143:
A.3 A.3 Study design Blood In addit
Page 144 and 145:
A.3 A.3 Study design the anterior n
Page 146 and 147:
A.3 A.3 Study design study. For exa
Page 148 and 149:
A.3 A.3 Study design large-size sto
Page 150 and 151:
A.3 A.3 Study design routinely prep
Page 152 and 153:
A.3 A.3 Study design Subjects who m
Page 154 and 155:
A.3 A.3 Study design A.3.6.3 reliab
Page 156 and 157:
A.3 A.3 Study design In addition, a
Page 158 and 159:
A.3 A.3 Study design Disease Questi
Page 160 and 161:
A.3 A.3 Study design Data routinely
Page 162 and 163:
A.3 A.3 Study design tial misclassi
Page 164 and 165:
A.3 A.3 Study design � The KORA c
Page 166 and 167:
A.3 A.3 Study design Table 3.16: Co
Page 168 and 169:
A.3 A.3 Study design Table 3.17: Co
Page 170 and 171:
A.4 A.4 Integrated Data Management
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
A.5 A.5 Methods for quality assuran
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
A.6 A.6 Planned statistical analyse
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
A.6 A.6 Table Planned 6.4: Expected
Page 206 and 207:
Page 208 and 209:
A.6 Planned statistical analyses an
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
A.7 A.7 Ethical aspects logical/gen
Page 220 and 221:
A.7 A.7 Ethical aspects The more ex
Page 222 and 223:
A.7 A.7 Ethical aspects pants, trav
Page 224 and 225:
A.7 A.7 Ethical aspects Data handli
Page 226 and 227:
A.7 Table 7.2 Availability of ident
Page 228 and 229:
A.7 A.7 Ethical aspects Should bios
Page 230 and 231:
A.7 A.7 Ethical aspects ing finding
Page 232 and 233:
A.7 A.7 Ethical aspects 206
Page 234 and 235:
C.1 C.1 Annex: Description of the s
Page 236 and 237:
Page 238 and 239:
Page 240 and 241:
Page 242 and 243:
Page 244 and 245:
Page 246 and 247:
Page 248 and 249:
Page 250 and 251:
Page 252 and 253:
Page 254 and 255:
Page 256 and 257:
Page 258 and 259:
C.1 C.1 Table Annex: 1: Cluster Des
Page 260 and 261:
Page 262 and 263:
Page 264 and 265:
Page 266 and 267:
Page 268 and 269:
Page 270 and 271:
Page 272 and 273:
Page 274 and 275:
Page 276 and 277:
Page 278 and 279:
Page 280 and 281:
Page 282 and 283:
C.2 C.2 Annex: Methods for Statisti
Page 284 and 285:
C.2 C.2 Annex: Methods for Statisti
Page 286 and 287: C.2 Table S6.5: Sample size needed
Page 288 and 289: C.2 C.2 Annex: Methods for Statisti
Page 296 and 297: C.3 References 17. Keil, U., et al.
Page 298 and 299: C.3 References 50. Benjamin, E.J.,
Page 300 and 301: C.3 References 85. Calle, E.E. and
Page 302 and 303: C.3 References 121. Walter, R., D.J
Page 304 and 305: C.3 References 155. Ross, R., Ather
Page 306 and 307: C.3 References 189. Ghiotto, F., et
Page 308 and 309: C.3 References 225. Schmidt, C.O.,
Page 310 and 311: C.3 References 260. Eussen, S., et
Page 312 and 313: C.3 References 294. McCrae, R.R. an
Page 314 and 315: C.3 References 327. Lynch, J.W., G.
Page 316 and 317: C.3 References 360. Mair, C., A.V.
Page 318 and 319: C.3 References 395. Lesourd, B., Nu
Page 320 and 321: C.3 References 431. Statistisches B
Page 322 and 323: C.3 References 462. Bundeszentrale
Page 324 and 325: C.3 References 494. Rammstedt, B. a
Page 326 and 327: C.3 References 526. Mack, F., et al
Page 328 and 329: C.3 References 560. Palatini, P., A
Page 330 and 331: C.3 References 590. Greenland, P.,
Page 332 and 333: C.3 References 623. Olin, A.C., et
Page 334 and 335: C.3 References 658. Pate, R.R., J.R
Page 338 and 339: C.3 References 727. Ryu, O.H., et a
Page 340 and 341: C.3 References 757. BSI-Standard 10
Page 342 and 343: C.3 References 790. Davis, C.E., et
Page 344: C.3 References 822. Hegenscheid, K.
show all

Scientific Concept of the National Cohort (status ... - Nationale Kohorte

Create successful ePaper yourself

Delete template?

Save as template?